Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.

Dutasteride works better than finasteride for hair loss, with both being safe to use.

α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.

Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.

Oral finasteride and dutasteride may negatively affect erectile function in rats.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

5ARIs like finasteride can help prevent prostate cancer and treat BPH, but guidelines should be updated to reflect this.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.